Zwijnaarde, Belgium
Zwijnaarde, Belgium

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies. Wikipedia.

SEARCH FILTERS
Time filter
Source Type

Patent
Ablynx | Date: 2017-07-19

The present invention relates to amino acid sequences, compounds and polypeptides binding to tumor necrosis factor alpha (TNF or TNF-alpha). In particular, the present invention relates to improved heavy-chain immunoglobulin single variable domains (also referred to herein as ISVs or ISVDs) binding to tumor necrosis factor alpha, as well as to proteins, polypeptides and other constructs, compounds, molecules or chemical entities that comprise such ISVDs, collectively TNF binders. Other aspects, embodiments, features, uses and advantages of the invention will be clear to the skilled person based on the disclosure herein.


Patent
Ablynx | Date: 2017-01-03

The present invention relates to amino acid sequences that are capable of binding to serum albumin; to proteins and polypeptides comprising or essentially consisting of such amino acid sequences; to nucleic acids that encode such amino acid sequences, proteins or polypeptides; to compositions, and in particular pharmaceutical compositions, that comprise such amino acid sequences, proteins and polypeptides; and to uses of such amino acid sequences, proteins and polypeptides.


Patent
Ablynx | Date: 2016-09-01

The present invention relates to a method for producing a domain antibody in a yeast, wherein the formation of disulfide bridges in the domain antibody is promoted. The method encompasses the addition of oxidizing agents, preferably oxidizing metal ions, preferably one or more selected from Cu2+, Fe2+, Fe3+ and Zn2+.


Amino acid sequences are provided that are directed against/and or that can specifically bind protein F of hRSV, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The amino acid sequences, polypeptides and therapeutic compounds and compositions provided by the invention show an improved stability, less immunogenicity and/or improved affinity and/or avidity for protein F of hRSV. The invention also relates to the uses of such amino acid sequences, polypeptides, compounds or constructs for prophylactic and/or therapeutic purposes.


Patent
Ablynx | Date: 2017-04-26

The present invention relates to immunoglobulins that specifically bind Kv1.3 and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the immunoglobulins of the present invention inhibit the activity of Kvl.3.


The present invention is based on the finding that administration of polypeptides comprising at least one Immunoglobulin single variable domains against vWF to human TTP patients provides a significant decrease in the time to response. The invention provides a polypeptide comprising at least one immunoglobulin single variable domain (ISVD) against von Willebrand Factor (vWF) for use in treating a vWF-related disease in a human in need thereof. The invention further relates to dosage unit forms, kits and medical uses for treating TTP.


Method for detecting and/or measuring anti-drug antibodies against a protein, polypeptide or other compound or molecule that comprises at least one immunoglobulin variable domain with an exposed C-terminal region in a sample, said method, comprising at least the steps of: a) contacting said sample with a capturing agent that is immobilized on a support, wherein said capturing agent is or essentially consists of said protein, polypeptide or other compound or molecule, under conditions such that any anti-drug antibodies against said protein, polypeptide or other compound or molecule can bind to said capturing agent; b) (optionally) removing any components or constituents present in said sample that do not bind to the capturing agent; c) detecting or measuring any anti-drug antibodies that have bound to the capturing agent, by contacting the complex of the capturing agent and any captured anti-drug antibodies with a detection agent, under conditions such that said detection agent can bind to (the complex of the capturing agent and) any captured anti-drug antibodies, wherein either: x) said capturing agent is or essentially consists of: (i) said protein, polypeptide or other compound or molecule (immobilized on the solid support); and (ii) 1-5 amino acid residues that are linked to the exposed C-terminal end of the immunoglobulin variable domain with the exposed C-terminal region that is comprised within the protein, polypeptide or other compound or molecule; y) said detection agent is or essentially consists of: (i) said protein, polypeptide or other compound or molecule; (ii) a detectable tag or label bound to said protein, polypeptide or other compound or molecule (either directly or via a suitable linker) and (iii) 1-5 amino acid residues that are linked to the exposed C-terminal end of the immunoglobulin variable domain with the exposed C-terminal region that is comprised within the protein, polypeptide or other compound or molecule.


The present invention relates to polypeptides derived from single domain heavy chain antibodies directed to Tumor Necrosis Factor-alpha. It further relates to single domain antibodies that are Camelidae VHHs. It further relates to methods of administering said polypeptides. It further relates to protocols for screening for agents that modulate the TNF-alpha receptor, and the agents resulting from said screening.


The present invention relates to amino acid sequences that are directed against RANK-L, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The invention also relates to nucleic acids encoding such amino acid sequences and polypeptides; to methods for preparing such amino acid sequences and polypeptides; to host cells expressing or capable of expressing such amino acid sequences or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, polypeptides, nucleic acids and/or host cells; and to uses of such amino acid sequences or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes.


Patent
Ablynx | Date: 2017-03-22

VH domain, in which: (i) the amino acid residue at position 1 12 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 1 10 is one of K or Q; and (iv) in each of cases (i) to (hi), the amino acid at position 1 1 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).

Loading Ablynx collaborators
Loading Ablynx collaborators